A Turning Point in Retinal Neovascular Diseases

News
Article

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Related Content
Site Logo

Early Experience of Aflibercept 8mg (EYLEA® 8mg) in Routine Clinical Practice

August 19th 2025
Article
Site Logo

Updates From Angiogenesis-2022

August 19th 2025
Podcast
Three ways we’re building confidence through evidence in myopia management

Three ways we’re building confidence through evidence in myopia management

August 19th 2025
Article
Site Logo

Updates from ASRS 2021

August 19th 2025
Podcast
Site Logo

Three-year outcomes of aflibercept 8mg in neovascular age related macular degeneration and diabetic macular edema

Sponsored by Bayer
August 19th 2025
Article
Clinical outcomes and patient satisfaction achieved with a corneal approach for managing presbyopia – a case with special significance

Clinical outcomes and patient satisfaction achieved with a corneal approach for managing presbyopia – a case with special significance

Arnaldo Espaillat, MD
August 19th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.